findmyKOL

Patrick Wen, MD

Enriched profile

Director, Neuro-Oncology Division, Brigham and Women's Hospital; Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Professor of Neurology, Harvard Medical School · Dana-Farber Cancer Institute

ORCID↗NPINone on file
RegionNot on fileSpecialtyMedical OncologyFocusGlioma Diagnosis and Treatment+4
Active KOLLatest publication2026Online presenceverified 2026PaymentsNot attributedNIH funding1990–2015Why? →

Patrick Wen is Director, Neuro-Oncology Division, Brigham and Women's Hospital; Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Professor of Neurology, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 1,915 publications with 89,244 citations (h-index 146); ClinicalTrials.gov lists 25 registered studies with this person as an investigator. Clarivate lists Patrick Wen as a Highly Cited Researcher (Cross-Field, 2018-2019, 2023-2024).

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Patrick Y. Wen is Director, Neuro-Oncology Division, Brigham and Women's Hospital at Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard Medical School (Boston, MA). The public record shows 1,915 publications with 89,244 citations (h-index 146), centered on Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Cancer, Hypoxia, and Metabolism. It also documents an investigator role on 25 registered clinical trials, 4 NIH-funded awards (1990–2015).

  • Most recent indexed publication: 2026 · Nature medicine
  • Top research focus: Glioma Diagnosis and Treatment
  • 25 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Neuro-Oncology / Glioma19 trialsGlioma11 trialsAstrocytoma9 trialsSarcoma8 trialsGliosarcoma8 trialsComa8 trialsOligodendroglioma7 trialsBrain Neoplasms3 trialsCentral Nervous System Neoplasms3 trialsNervous System Neoplasms3 trialsMeningioma2 trialsHemangiopericytoma1 trialLung Cancer (NSCLC/SCLC)1 trialNeoplasm Metastasis1 trialSmall Cell Lung Carcinoma1 trial

Research focus

OpenAlex concept fingerprint
Glioma Diagnosis and TreatmentBrain Metastases and TreatmentCancer, Hypoxia, and MetabolismRadiomics and Machine Learning in Medical ImagingNeuroblastoma Research and Treatments

Drugs & molecules

across trials, industry payments and publications
TemozolomideClinical trials8Industry payments—Publications4BevacizumabClinical trials3Industry payments—Publications2NivolumabClinical trials2Industry payments—Publications2
9 more drug records behind the reveal.Reveal →

Works with

trial sponsors and companies reporting payments
Dana-Farber Cancer InstituteClinical trials8Industry payments—Patrick Y. Wen, MDClinical trials6Industry payments—National Cancer Institute (NCI)Clinical trials4Industry payments—
7 more company records behind the reveal.Reveal →

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,915publications

Distinct works indexed by OpenAlex, matched via ORCID; 58 in PubMed.

89,244citations

Total citations across indexed works.

146h-index

Hirsch index (OpenAlex). i10-index 674.

Clinical & industry

trials, payments and federal funding
25clinical trials

Investigator role on registered studies.

View trials ↓
—payment companies

Not shown. No U.S. clinical registration on file.

4NIH grants · 1990–2015

Federally funded research awards.

View funding ↓

This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →

Contact

An office address from a public listing. This research profile has no federal registry record to draw from.

Office address

60 Fenwood Road, 1st Floor, Hale Building for Transformative Medicine, Boston, MA 02115

From the cited public source.Collected 27 Aug 2026.View source ↗

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 25 registered studies on ClinicalTrials.gov. The most recent:

22 more trial records behind the reveal.Reveal →

Industry payments

Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →

NIH funding

Updated 27 Aug 2026

4 NIH research awards on record, funded 1990–2015 per NIH RePORTER. The latest:

16 more award records behind the reveal.Reveal →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

53 more publications behind the reveal.Reveal →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Malignant Gliomas in Adults
    4,244 citations2008
    doi.org ↗
  2. 02
    Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
    3,830 citations2010
    doi.org ↗
  3. 03
    Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
    2,445 citations2009
    doi.org ↗
  4. 04
    AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
    1,765 citations2007
    doi.org ↗
  5. 05
    Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
    1,433 citations2018
    doi.org ↗
1,910 more cited works behind the reveal.Reveal →

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Timothy F. Cloughesy519David A. Reardon442Tracy T. Batchelor328
37 more collaborators behind the reveal.Reveal →

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/patrick-wen-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Patrick-Y-Wen-38800436

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • Other

    curetoday.com/view/how-fda-approved-modeyso-works-to-treat-glioma

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curetoday.com ↗
  • Other

    onclive.com/view/fda-approval-insights-dordaviprone-in-h3k27m-mutated-diffuse-midline-glioma-with-patrick-y-wen-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • X / Twitter

    x.com/DanaFarberNews/status/1970178782364303773

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Medical College of St. Bartholomew's Hospital, University of London

    1981
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗

Editorial & leadership roles

journal and society appointments
  • Former Editor-in-Chief

    Neuro-Oncology

    2014
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pmc.ncbi.nlm.nih.gov ↗
  • Executive Editor

    Neuro-Oncology (Oxford Academic / Society for Neuro-Oncology journal)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →academic.oup.com ↗
  • Former President

    Society for Neuro-Oncology (SNO)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
4 more roles behind the reveal.Reveal →

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Cross-Field
    2018201920232024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Secondary affiliations

appointments beyond the home institution
  • Member

    Science Advisory Board, CNS Pharmaceuticals

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biospace.com ↗
  • Scientific Advisor

    Candel Therapeutics

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →candeltx.com ↗
  • Course Director

    Harvard Medical School Professional, Corporate, and Continuing Education

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →learn.hms.harvard.edu ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.